Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$0 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-7.8 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
10.7
Industry P/E
--
EV/EBITDA
-0.4
Div. Yield
0 %
Debt to Equity
-3.7
Book Value
$--
EPS
$-3
Face value
--
Shares outstanding
26,832,457
CFO
$-610.57 Mln
EBITDA
$-710.13 Mln
Net Profit
$-672.89 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Syros Pharmaceuticals (SYRS)
| -- | -- | -- | -99.8 | -95.8 | -92.3 | -- |
|
BSE Sensex*
| -13.7 | -10.1 | -14.2 | -3.8 | 7.4 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Syros Pharmaceuticals (SYRS)
| -97.0 | 117.0 | -89.0 | -70.0 | 57.0 | 24.1 | -42.6 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Syros Pharmaceuticals (SYRS)
|
0.0 | 0.0 | 0.4 | -97.8 | -23,959.8 | -- | -- | 10.7 |
| 62.9 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 228.2 | 13,405.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 66.6 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 44.0 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 91.2 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 7.1 | 6,847.2 | 113.3 | -351.4 | -211.0 | 71.1 | -- | 0.0 | |
| 529.8 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 489.5 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 319.3 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in... Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts. Read more
Scientific Founder, Member of Scientific Advisory Board & Director
Dr. Richard A. Young Ph.D.
Scientific Founder, Member of Scientific Advisory Board & Director
Dr. Richard A. Young Ph.D.
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Syros Pharmaceuticals Inc (SYRS) is $0.00 (NASDAQ) as of 01-Apr-2026 09:30 EDT. Syros Pharmaceuticals Inc (SYRS) has given a return of -95.78% in the last 3 years.
Since, TTM earnings of Syros Pharmaceuticals Inc (SYRS) is negative, P/E ratio is not available.
The P/B ratio of Syros Pharmaceuticals Inc (SYRS) is 10.65 times as on 27-Mar-2026, a 170 premium to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-1.40
|
13.81
|
|
2022
|
-1.05
|
0.78
|
|
2021
|
-0.24
|
0.24
|
|
2020
|
-0.79
|
0.74
|
|
2019
|
-0.40
|
0.38
|
The 52-week high and low of Syros Pharmaceuticals Inc (SYRS) are Rs 0.00 and Rs 0.00 as of 02-Apr-2026.
Syros Pharmaceuticals Inc (SYRS) has a market capitalisation of $ 0 Mln as on 27-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Syros Pharmaceuticals Inc (SYRS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.10
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.